GPP 2022 Guidelines

The 2022 update of the Good Publication Practice (GPP 2022) guidelines, a key guidance document for the publication of company-sponsored biomedical research, was published in Annals of Internal Medicine on August 30, 2022. Access GPP 2022 in Annals of Internal Medicine.

DeTora LM, Toroser D, Sykes A, et al. Good Publication Practice (GPP) guidelines for company-sponsored biomedical research: 2022 update. Ann Intern Med. 30 August 2022. [Epub ahead of print]. doi:10.7326/M22-1460
(To download a PDF of GPP 2022 from the Annals of Internal Medicine website, you can open a Free Account if you do not have a journal subscription.)

GPP 2022 is the third update of the original GPP guidelines, which were published in 2003 and updated in 2009 as GPP2 and in 2015 as GPP3. GPP 2022 was reorganized to provide ready-to-go advice for teams and give an overview of the basic best practices for planning and developing biomedical publications. A table mapping GPP3 contents to the GPP 2022 update is included.

With the 2022 update, the GPP Steering Committee focused on several new areas, including alliances, the role of patients in publications, and policies and procedures. Guidance and process steps are offered for steering committees, publication plans, publication working groups, authorship and contributorship determination, and publication process. Advice is also provided on the use of social media, documentation, and enhanced content, including plain language summaries. Another important feature is inclusivity, which is considered in terms of demographic characteristics and geography, as well as job roles.

Translations of GPP 2022

Translations of GPP 2022 into the Chinese language and Japanese language are being made available, with the aim of expanding the global reach of GPP 2022 guidelines and broadening the adoption of good publication practices.

Chinese Translation
Access the Chinese translation of the GPP 2022 publication and its supplement (available as of April 2023).

ISMPP would like to acknowledge Lilly China Scientific Communication team for their work in developing the Chinese translation of GPP 2022: Project led by Chunli Shi and Yunpeng Guo; Translation done by Yunjing Zhang, Zipei Xiao, Mengting Zhang, Yu Mao, Yunpeng Guo, Linmin Chen, Fangling Zhang, Shu Wang and Chunli Shi. ISMPP would also like to thank Ronnie Lin (Hasten Biopharma) and Greta Ge (Lilly China Drug Development and Medical Affairs Center, Lilly Suzhou Pharmaceutical Co. Ltd.) for their review and proofread of the Chinese translation.

Japanese Translation
The Japanese translation of GPP 2022 is in process and will be made available once the translation is completed.

Frequently Asked Questions

For further information:

  • WATCH the recording of a Special 90-minute ISMPP U webinar on GPP 2022, held September 21, 2022.

  • GPP 2022 article in ISMPP’s The MAP newsletter. 

  •  ISMPP GPP 2022 press release

GPP3 and Historical Archives

For information on GPP3 Guidelines from 2015, click here

Back to top